SG Americas Securities LLC Buys 57,685 Shares of Amicus Therapeutics, Inc. $FOLD

SG Americas Securities LLC lifted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 491.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 69,420 shares of the biopharmaceutical company’s stock after purchasing an additional 57,685 shares during the quarter. SG Americas Securities LLC’s holdings in Amicus Therapeutics were worth $547,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in FOLD. Norges Bank bought a new stake in shares of Amicus Therapeutics in the 2nd quarter worth about $18,540,000. Jump Financial LLC grew its position in Amicus Therapeutics by 246.3% in the second quarter. Jump Financial LLC now owns 1,406,563 shares of the biopharmaceutical company’s stock worth $8,060,000 after acquiring an additional 1,000,395 shares in the last quarter. Advantage Alpha Capital Partners LP bought a new stake in Amicus Therapeutics during the second quarter worth approximately $201,000. 683 Capital Management LLC raised its position in Amicus Therapeutics by 249.1% during the second quarter. 683 Capital Management LLC now owns 960,000 shares of the biopharmaceutical company’s stock valued at $5,501,000 after purchasing an additional 685,000 shares during the period. Finally, Rice Hall James & Associates LLC lifted its stake in shares of Amicus Therapeutics by 24.4% in the 3rd quarter. Rice Hall James & Associates LLC now owns 3,434,717 shares of the biopharmaceutical company’s stock valued at $27,066,000 after purchasing an additional 674,403 shares during the last quarter.

Amicus Therapeutics Trading Up 0.0%

NASDAQ FOLD opened at $14.28 on Friday. Amicus Therapeutics, Inc. has a one year low of $5.51 and a one year high of $14.38. The company has a debt-to-equity ratio of 1.70, a quick ratio of 2.09 and a current ratio of 2.99. The company has a market capitalization of $4.48 billion, a price-to-earnings ratio of -356.79 and a beta of 0.42. The company’s 50-day simple moving average is $12.23 and its two-hundred day simple moving average is $9.27.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.05. The firm had revenue of $169.06 million for the quarter, compared to the consensus estimate of $165.24 million. Amicus Therapeutics had a negative net margin of 2.35% and a positive return on equity of 6.95%. The company’s quarterly revenue was up 19.5% on a year-over-year basis. During the same period last year, the firm earned $0.10 earnings per share. Equities analysts forecast that Amicus Therapeutics, Inc. will post 0.15 EPS for the current fiscal year.

Insider Activity

In other news, insider David Michael Clark sold 25,643 shares of the firm’s stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $9.51, for a total value of $243,864.93. Following the completion of the sale, the insider owned 322,618 shares of the company’s stock, valued at $3,068,097.18. This trade represents a 7.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jeff Castelli sold 76,158 shares of the firm’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $10.16, for a total value of $773,765.28. Following the completion of the sale, the insider directly owned 439,318 shares of the company’s stock, valued at approximately $4,463,470.88. This represents a 14.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 420,450 shares of company stock valued at $4,730,250. Company insiders own 2.20% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on FOLD shares. Wall Street Zen raised Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Guggenheim cut shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 5th. Leerink Partners lowered shares of Amicus Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $17.00 to $14.50 in a report on Monday, December 29th. Citigroup reaffirmed a “neutral” rating and set a $14.50 price target (down from $17.00) on shares of Amicus Therapeutics in a research note on Monday, December 22nd. Finally, TD Cowen lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 price objective on the stock. in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Amicus Therapeutics has an average rating of “Hold” and an average price target of $15.55.

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.